Article:Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. (5643039)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. and the publication date was 2017-08-27. The initial author is Cristina Mega.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Journal of Diabetes Research

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes

  • Cristina Mega
  • Edite Teixeira-de-Lemos
  • Rosa Fernandes
  • Flávio Reis

1Agrarian School of Viseu (ESAV), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal

2Centre for the Study of Education, Technologies and Health (CI&DETS), Polytechnic Institute of Viseu (IPV), 3500-606 Viseu, Portugal

3Institute of Pharmacology and Experimental Therapeutics and Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal

4CNC.IBILI Research Consortium, University of Coimbra, 3004-504 Coimbra, Portugal

Publication date (ppub): /2017

Publication date (epub): 8/2017


Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients. It is also acknowledged as an independent risk factor for cardiovascular disease (CVD). Since sitagliptin was approved, many studies have been carried out revealing its ability to not only improve metabolic control but also ameliorate dysfunction in various diabetes-targeted organs, especially the kidney, due to putative underlying cytoprotective properties, namely, its antiapoptotic, antioxidant, anti-inflammatory, and antifibrotic properties. Despite overall recommendations, many patients spend a long time well outside the recommended glycaemic range and, therefore, have an increased risk for developing micro- and macrovascular complications. Currently, it is becoming clearer that type 2 diabetes mellitus (T2DM) management must envision not only the improvement in glycaemic control but also, and particularly, the prevention of pancreatic deterioration and the evolution of complications, such as DN. This review aims to provide an overview of the current knowledge in the field of renoprotective actions of sitagliptin, namely, improvement in diabetic dysmetabolism, hemodynamic factors, renal function, diabetic kidney lesions, and cytoprotective properties.


1. Introduction

Type 2 diabetes mellitus (T2DM) is recognized as being a group of chronic diseases characterized by hyperglycaemia where the importance of protecting the body from excessive glucose circulation cannot be overstated. The central key features of T2DM are a defect in insulin resistance and/or insulin secretion, which lead to hyperglycaemia and disrupt the normal relationship between insulin sensitivity and pancreatic β-cell function [[1]]. Degeneration of Langerhans islets with β-cell loss is secondary to insulin resistance and is regarded as the most important lesion for disease progression [[2][5]]. Currently, eight central players are considered to be involved in T2DM pathophysiology—the ominous octet—composed by muscle/liver insulin resistance, β-cell failure, enhanced lipolysis, hyperglucagonaemia, dysregulation of hepatic glucose production, brain insulin resistance, increased renal glucose reabsorption, and incretin hormone [glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] deficiency, all contributing to a persistent state of hyperglycaemia [[6]]. GLP-1 and GIP are peptide hormones that are involved in the physiologic regulation of glucose homeostasis. These hormones are secreted from the gastrointestinal tract after a meal and stimulate insulin secretion in a glucose-dependent manner [[7]]. In T2DM, there is an “incretin defect,” manifested through the reduction in incretin bioavailability, which in part is due to their rapid inactivation by dipeptidyl peptidase-4 (DPP-4) [[8]]. It is now also acknowledged that biochemical pathways, such as apoptosis, low-grade inflammation, and oxidative stress, which are mainly fuelled by hyperglycaemia and hyperlipidaemia, are key mediators of insulin resistance and β-cell dysfunction and are involved in the overall aggravation of the diabetic state [[3], [9][15]]. The persistent dysfunction of these metabolic pathways in the “ominous octet” organs, through the direct and indirect effects of hyperglycaemia, seems to have an important role in the development of T2DM's major long-term complications [[16], [17]].

Generally, diabetic complications are divided into macrovascular (coronary artery disease, peripheral arterial disease, and stroke) and microvascular complications (nephropathy, retinopathy, and neuropathy). T2DM-induced micro- and macrovascular complications and their pathologies are major contributors to disease morbidity and mortality, respectively [[18], [19]]. It is now known that inflammation promotes development and progression of diabetic microangiopathy, which trigger extracellular matrix protein synthesis and capillary basement membrane thickening; these conditions contribute to the development of severe diabetic complications, such as nephropathy, retinopathy, and neuropathy [[20][22]].

Diabetic nephropathy (DN) originates insidious chronic kidney disease (CKD) and is recognized as the single most common cause of end-stage renal disease (ESRD) and one of the main causes of death in diabetic patients worldwide, being also acknowledged as an independent risk factor for cardiovascular disease (CVD) [[23][25]].

T2DM can generally be prevented with interventions such as change in dietary habits and physical activity. However, individuals with established diabetes should be treated with antidiabetic drugs [[26], [27]]. T2DM therapy has vastly improved in the last 10 years with the availability of new drugs and drug classes. These pharmacological agents improve glycaemic control by increasing insulin secretion, ameliorating insulin action, decreasing hepatic gluconeogenesis, and delaying the absorption of carbohydrates [[28], [29]]. Currently, T2DM can be managed with biguanides, sulfonylureas, meglitinide derivatives, alpha-glucosidase inhibitors, thiazolidinediones, selective sodium-glucose transporter-2 (SGLT2) inhibitors, insulins, amylinomimetics, bile acid sequestrants, dopamine agonists, and incretin-based therapies, which include glucagon-like peptide1 (GLP-1) agonists and DPP-4 inhibitors, of which sitagliptin was the first to be discovered and marketed [[29], [30]]. Moreover, these drugs may be used in various therapeutic combinations as an add-on therapy for improved management of hyperglycaemia [[29]].

Treatment regimens of T2DM that reduce the levels of HbA1c to near or below 7% are able to significantly reduce the risk of microvascular complications and diabetes-related death [[31][36]]. Current recommendations by the consensus of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) justify the selection of appropriate treatment based on its capability to achieve and maintain desired glycaemic goals [[36][38]]. Despite all recomendations, many patients spend a long time well outside the target glycaemic range and, therefore, have an increased risk for developing micro- and macrovascular complications [[6], [39]]. Currently, it is becoming clearer that T2DM management must envision not only glycaemic control but also and particularly, the mechanisms behind progression of pancreatic deterioration and evolution of diabetic complications [[40], [41]].

The ground-breaking incretin-based therapies that encompass GLP-1 agonists and DPP-4 inhibitors seem to address a previously unmet need in diabetes by modulating glucose supply [[42], [43]]. In fact, DPP-4 inhibitors, and especially sitagliptin, have progressively increased their therapeutic prominence in the management of T2DM by their capability to potentiate incretin activity. Various studies have described many pleiotropic effects of sitagliptin on various organs and tissues. The knowledge that DPP-4 has the highest expression levels in the kidneys of mammals, which is additionally upregulated in DN [[44]], indicates that DPP-4 inhibition by sitagliptin is a plausible therapeutic target for management of diabetic nephropathy.

This review outlines the evidence found in previous studies regarding the renoprotective action of sitagliptin in DN, focusing on renal function and lesions, as well as kidney tissue cytoprotective properties, particularly its antiapoptotic, antifibrotic, anti-inflammatory, and antioxidant properties.

2. The Incretin System in Diabetic Nephropathy

2.1. Overview of DN Pathophysiology

The kidney, besides contributing to the aggravation of hyperglycaemia in T2DM through gluconeogenesis [[45]] and glucose reabsorption, does not remain unscathed through diabetic evolution, developing progressive lesions and functional impairments that lead to DN [[46]]. Dysmetabolism, with a central role for chronic hyperglycaemia, and hemodynamic factors, namely, overactivity of the renin-angiotensin-aldosterone system (RAAS) and vascular endothelial growth factor (VEGF) deficiency, have key roles in the pathophysiology of DN. Chronic hyperglycaemia and dyslipidaemia induce mitochondrial deregulation and oxidative stress in kidney cells, which activate several metabolic pathways, including protein kinase C [[47]], nonenzymatic glycation [[48]], oxidative stress [[49][54]], and inflammation [[55], [59]].

Inflammatory response is mediated by diverse types of inflammatory cells (including macrophages, monocytes, and leukocytes) and molecules (such as adhesion molecules, chemokines, and cytokines, namely, TNF-α and IL-1β) [[55], [60]]. Besides altering glomerular hemodynamics and promoting increased vascular permeability, TNF-α activates several signalling pathways leading to apoptosis and necrosis. IL-1β also modifies vascular permeability and increases the expression of chemokines that induce proliferation and synthesis of extracellular matrix in the mesangium [[57]]. As inflammation persists, renal tissues are damaged, occurring endothelial dysfunction, mesangial nodule formation (Kimmelstiel-Wilson bodies), renal fibrosis, and apoptosis [[55], [60]].

Hemodynamic factors [[61], [62]] predominantly mediated by angiotensin II play a role via overactivity of the RAAS and promotion of VEGF deficiency. Interaction of metabolic factors, such as obesity and chronic hyperglycaemia, alters vasoactive regulating mechanisms of afferent and efferent arteriolar tonus, leading to increased glomerular capillary hydrostatic pressure, hyperperfusion, hyperfiltration, and microalbuminuria. These early renal hemodynamic changes, combined with systemic hypertension, are important in the development and progression of renal disease in T2DM [[63]].

Albuminuria is mostly glomerular in origin, as albumin must cross the glomerular filtration assembly, which is composed of three main cellular barriers that are of utmost importance for the ultrafiltration process, the fenestrated glomerular endothelial cells, glomerular basement membrane (GBM), and glomerular epithelial cells or podocytes. Alterations in this three-layered structure, like increased intraglomerular pressure, loss of negatively charged glycosaminoglycans in the basement membrane, and further in disease evolution, and increase in basement membrane pore size, contribute to albuminuria [[64]]. An increasing number of proteins have been identified to be present in foot projections of podocytes. Nephrin is a zipper-like protein that plays a functional role in the structure of the slit diaphragm. The spaces between the teeth of the zipper allow selective transport of small molecules (such as glucose and water) retaining, however, large proteins. Evidence suggests that nephrin could play a key role in glomerular filtration barrier and development of proteinuria as it is found to be downregulated in kidney failure and in diabetic rats [[51]]. In diabetes, early flattening and retraction of podocytes' foot processes are associated with thickening of the GBM. Thickening of GBM, as well as accumulation of mesangial matrix, and increased numbers of mesangial cells are considered as initial microscopic abnormalities. As the disease progresses, there is a close relationship between mesangial expansion and declining of glomerular filtration. Mesangial expansion also correlates inversely with capillary filtration surface area, which itself correlates to glomerular filtration rate [[64]]. Long-term persistence of the previous factors ultimately induces histological abnormalities in glomeruli, tubules, interstitium, and renal vascular tissues, affecting basement membranes, podocytes, endothelial, and mesangial cells, which eventually become irreversible [[64][68]].

The cumulative presence of cooperative risk factors, namely, obesity, hypertension, insulin resistance, hyperglycaemia, dyslipidaemia, and microalbuminuria, appears to support not only the aggravation of CKD but also the development of CVD called the cardiorenal metabolic syndrome [[69]]. However, the underlying mechanisms of micro- and macrovascular complications of diabetes are not yet completely clarified. It seems that diabetic microangiopathy in conjunction with the aforementioned diabetogenic factors, together with neovascularization of vasa vasorum, can lead to macrovascular complications. Consequently, alterations in small arteries and capillaries may be responsible not only for the enduring microvascular complications but also for CVD in diabetes and, thus, may constitute one more link between DN and CVD [[18]].

2.2. The Role of the Incretin System in the Pathophysiology of DN

The presence of the incretin hormone GLP-1 and of its receptor (GLP-1R) in the kidneys suggests that the incretin system can play a role in the modulation of kidney function [[70], [71]]. Incretin dynamics, which are significantly altered in T2DM, seem also to be implicated in alteration of vascular tonus, natriuretic, and diuretic properties in the kidney [[72]]. The localization of GLP-1R in endothelial cells and in the proximal renal tubules plays a role in regulating the composition of urine. Stimulation of the GLP-1R in blood vessels results in relaxation of smooth muscle and increased renal blood flow [[73]].

In the normal kidney, stimulation of GLP-1R by GLP-1 results in inactivation of the Na+/H+ exchanger isoform 3 (NHE3) transporter, blocking Na+ and other electrolytes retrieval from tubular fluid, thus resulting in natriuresis and water loss, and possibly, lowered blood pressure [[74]]. However, DPP-4 has its highest cellular expression in the kidneys of mammals, being found in the brush border of the proximal tubules, endothelium of the glomerular capillaries, and epithelium of Bowman's capsule [[8], [44], [75]]. In T2DM, DPP-4 is additionally upregulated in glomeruli of patients with DN, being implicated in the reduction of the half-life of GLP-1 in the kidney [[44], [76]] and altering its natriuretic and diuretic properties [[76]].

Other pathophysiological interventions by DPP-4 seem to involve its interaction with extracellular matrix proteins in the kidney during the development and evolution of DN, but there is still insufficient data demonstrating that selective DPP-4 inhibition is able to affect these independent interactions [[75]]. The association between DPP-4 and integrin β1 appears to promote endothelial-to-mesenchymal transition (EndMT) by negatively regulating endothelial viability signalling via suppression of the VEGF-receptor 2 and induction of VEGF-receptor 1 in endothelial cells. It seems that DPP-4 inhibition is capable of inhibiting EndMT and transforming growth factor-β2- (TGF-β2-) induced Smad3 phosphorylation, and thus, the progression to renal sclerosis. EndMT is a known contributor to the accumulation of activated fibroblasts and myofibroblasts in kidney fibrosis [[77]].

Furthermore, DPP-4 might be implicated in the inactivation of stromal-derived factor-1 alpha (SDF-1α), a chemokine linked to the migration of hematopoietic and endothelial progenitor cells (EPCs) to sites of ischemic injury, involved in tissue repair and in the response to tissue hypoxia [[44]]. It has been reported that DPP-4 inhibition is able to recruit EPCs to sites of [[78]].

Direct effects of DPP-4 on immune cells and indirect effects through GLP-1-dependent and GLP-1-independent pathways suggest that enzyme inhibition may have beneficial effects beyond glycaemic control, which may contribute to CKD and CVD outcomes [[71]].

3. Sitagliptin

3.1. Pharmacokinetic and Pharmacodynamic Properties of Sitagliptin

Sitagliptin is an oral antidiabetic drug with a recommended dose of 100 mg once a day. Oral absorption is not affected by food. Sitagliptin displays 87% of bioavailability and a reversible fraction bound to plasma proteins of 38% [[79]]; its half-life is around 12.4 hours; hepatic metabolism of sitagliptin is minimal, mainly by cytochrome P450 3A4, while excretion occurs mainly (70–80%) by the kidney in its unchanged form, with a renal clearance of approximately 350 ml/min [[80]]. In general, the pharmacokinetic profile of sitagliptin is similar in both healthy volunteers and T2DM patients. The pharmacokinetic properties of the drug have also been evaluated in special patient populations with varying grades of hepatic and renal dysfunction. As a result of its metabolism and elimination route, dose adjustment is only required in patients with severe renal insufficiency, being effective and safe in patients with mild/moderate renal or hepatic impairment [[81][85]]. No dosage adjustment is necessary related to age, gender and race, or body mass index. Sitagliptin also has a low propensity for pharmacokinetic drug interactions [[7]].

Sitagliptin is a potent and highly selective DPP-4 competitive inhibitor that does not affect the closely related enzymes DPP-8 or DPP-9 at therapeutic concentrations [[75][86]]. Sitagliptin acts by inhibiting over 80% of the activity of DPP-4 enzyme (at 12 h postdose for 50 mg/day and at 24 h postdose for ≥100 mg/day), which is responsible for degrading GLP-1, preventing therefore its inactivation. This increases and prolongs plasma concentrations of the active form of GLP-1, allowing the consequent stimulation of insulin synthesis and secretion from pancreatic β-cells in a glucose-dependent manner [[87][90]].

As T2DM patients exhibit relative resistance to the actions of GIP [[91]], the main goals of DPP-4 inhibitors are to prolong the beneficial effects of endogenous GLP-1 [[92]] in order to maintain its insulinotropic activity [[93]]. Glycaemic levels are then further regulated by the resulting higher insulin levels and glucagon suppression from the direct action of GLP-1 on pancreatic α-cells [[94]]. Sitagliptin reduces blood glucose levels, in either the postprandial or the fasting state. It works differently from the previous drugs available for diabetes treatment and is orally active [[95], [96]].

Clinical trials have demonstrated the efficacy of sitagliptin in terms of improving glycaemic control in T2DM patients, used as either monotherapy, initial combination therapy (usually with a fixed dose combination of sitagliptin/metformin) or add-on therapy to metformin or to other antihyperglycaemic drugs, with or without metformin. Sitagliptin showed efficacy in decreasing HbA1c, fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) levels and also increasing the proportion of patients achieving target HbA1c levels (<7.0%), as shown in several clinical studies [[79], [97][100]].

3.2. Sitagliptin Affords Protection in Organs Targeted by Diabetes

Experimental studies performed in animal models of T2DM that were treated with sitagliptin showed remarkable beneficial effects on glucose and HbA1c levels, an improvement of insulin resistance, together with promotion of weight loss and amelioration of lipid profile [[101][110]]. Moreover, sitagliptin was able to consistently alleviate oxidative stress and inflammation, which are key players in diabetes pathophysiology and in the development of DN [[51], [57], [103], [111]].

Sitagliptin promotes a conjoined improvement in dyslipidaemia and hypertension, which are interactive factors for CKD and CVD [[104], [107][111]]. Sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms [[110]]. Several reports have corroborated the cardiovascular protective aspects and have also identified cytoprotective properties, such as a decrease in heart oxidative stress, inflammation, and apoptosis [[19], [78], [103], [112][118]]. Concerning the impact of sitagliptin on lipid profiles in T2DM patients, the majority of studies reported a beneficial effect on triglycerides (TGs), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) [[119], [120]]. DPP-4 inhibition also appears to improve endothelial function in diabetic patients, in both a GLP-1-dependent and GLP-1-independent manner [[121], [122]]. Furthermore, sitagliptin was able to increase EPC levels in diabetic patients [[78]].

Our research group has extensively studied the protective effects of sitagliptin on various organs targeted by diabetes, namely, the pancreas, retina, and kidney, in an animal model of T2DM. Sitagliptin was able to prevent the aggravation of both endocrine and exocrine pancreatic histopathological lesions and presented antiapoptotic and anti-inflammatory properties, as well as decreased insulin resistance and pro-proliferative and angiogenic actions [[103], [123]]. In the retina, sitagliptin treatment prevented changes in the endothelial subcellular distribution of tight junction proteins and improved nitrosative stress and inflammatory and apoptotic states [[124]]. Later studies in type 1 diabetic rats revealed that sitagliptin could prevent the increase in blood-retinal barrier permeability and decrease the retinal inflammation state and neuronal apoptosis [[125]]. Our studies in the kidney also revealed protective properties [[8], [126]]. Other authors have also found diabetic lesion improvement in the pancreas associated to antiapoptotic, pro-proliferative [[111], [127][131]], and anti-inflammatory properties [[132][134]].

Besides decreasing insulin resistance [[5], [135], [136]] and improving hepatic insulin sensitivity, sitagliptin seems also to prevent steatosis [[137]] through GLP-1R signalling in the liver and reduction of endoplasmic reticulum stress [[138]]. GLP-1R has been found to be expressed in human hepatocytes [[138]]. However, other authors failed to detect GLP-1R mRNA transcripts in human, rat, or mouse liver [[139]]. Antiapoptotic effects on human hepatoma cells by DPP-4 inhibition have also been identified [[140]].

Treatment of nonobese diabetic mice with sitagliptin not only prevented linoleic acid-induced adipose tissue hypertrophy but also protected against adipose tissue inflammation [[129], [137]].

In T2DM rats with uncontrolled neuropathy, sitagliptin as add-on to insulin therapy produced neuroprotective effects and ameliorated hyperalgesia, oxidative stress, and inflammation, more than either drug alone [[141]].

4. Sitagliptin Affords Renoprotection in Diabetic Nephropathy

4.1. Effects of Sitagliptin on Renal Function

The effects of sitagliptin on DN, using the ZDF rat, noticeably reduced renal dysfunction and injury in this model. In fact, sitagliptin treatment was able to decrease blood urea nitrogen (BUN) levels to values identical to those observed in lean control rats, suggesting an amelioration of renal function [[126]]. Nevertheless, serum creatinine levels were unchanged between study groups, which are in accordance with others using the ZDF rat as an animal model [[106], [142]].

Direct vasodilator effects have also been described for DPP-4 inhibitors [[143]]. In this regard, interactions of angiotensin II and DPP-4/GLP-1 signalling have been proposed as one of the mechanisms for the blood pressure- (BP-) lowering effect of DPP-4 inhibition [[144]]. Sitagliptin seems to be able to lower BP in a GLP-1-dependent manner through GLP-1R localized in renal endothelial cells and in the proximal renal tubules, which play a role in regulating the composition of urine. DPP-4 inhibition by sitagliptin administration increases GLP-1 availability which stimulates GLP-1R in blood vessels, through the sequential activation of the PKA/LKB1/AMPKα/eNOS axis, thus inducing relaxation of smooth muscle and improvement of renal blood flow [[143], [145]].

There are solid evidences that the proximal tubules play a major role in microalbuminuria in DN, namely, in early stages of the disease [[146], [147]]. In addition, stimulation of GLP-1R in the proximal tubules results in increased loss of salt, water, and electrolytes in urine. The latter occurs as the GLP-1Rs situated in proximal convoluted tubules of the kidneys are functionally linked to NHE3 transporters. NHE3 promotes recovery of Na+ and other electrolytes from the tubular fluid (and thus from urine), thereby returning them into the circulation. Activation of the GLP-1R by GLP-1 results in inactivation of NHE3, which leads to increased Na+ loss in urine, consequentially, through osmotic effects, to increased fluid loss, and possibly, to lowered BP [[74]]. An association of NHE3 with DPP-4 was found in the proximal tubule, which might affect NHE3 surface expression and/or activity [[148]]. Furthermore, DPP-4 inhibition, in experimental models of obesity and heart failure, was able to upregulate megalin, a receptor that mediates endocytosis of proteins in the proximal tubule [[149], [150]]. DPP-4 inhibition improved kidney injury and proteinuria in obese rodent models [[124], [150][152]]. Consistently, Aroor et al. have demonstrated that increased DPP-4 activity, evoked by angiotensin II, suppresses megalin expression in mice, an effect that was partially abolished by using a DPP4 inhibitor [[153]].

Effects of GLP-1 on lowering BP have been reported in both animal and human studies [[154], [155]]. The natriuretic and diuretic properties of GLP-1 were proved in infusion studies in a rat model of salt sensitivity by chronic intravenous infusion of GLP-1 [[72]]. Although glycaemic levels affect renal pathophysiology, the previously mentioned effects of incretin protection appear to be independent of these levels, although the underlying mechanisms still remain to be clarified [[156], [157]]. Diuretic and natriuretic actions of DPP-4 inhibitors seem to offer renoprotection in the setting of hypertension and other disorders of sodium retention. However, in the case of sitagliptin, available data is not yet sufficient to confirm this protective effect [[74], [76]].

4.2. Effects of Sitagliptin on Renal Lesions

Although DN has been traditionally considered primarily a glomerular disease, it is now widely accepted that the rate of function deterioration correlates best with the degree of renal tubulointerstitial fibrosis. This suggests that although the primary event is a condition marked by glomerular changes resulting in proteinuria, the long-term outcome is determined by events in the renal interstitium [[158], [159]].

In preclinical studies, initial histopathological observations of DN focused mainly on glomerular lesions, alluding, only briefly, to tubulointerstitial lesions and considering their presence as a secondary lesion of DN [[160], [161]]. The description of vascular lesions in the kidney was absent in animal model studies and could be scarcely found in a few human DN reports. Thus envisioning evaluation conformity and better correlation between human nephropathy and renal lesions observed in animal models, the international histopathological classification, currently approved for human DN, should be adopted in these studies. This histological classification was established in 2010 and evaluates glomerular, tubulointerstitial, and vascular lesions in a semiquantitative manner, according to their severity and tissue distribution [[162]].

In experimental animal models, diabetic glomerular lesions initially display thickening of the GBM and mesangial expansion, which are followed by the appearance of nodular sclerosis and vascular pole hyalinization, accompanied by glomerular hypertrophy. With disease aggravation, glomerulosclerosis and glomerular atrophy become evident (Figure 1(a)), confirming the link between diabetes (hyperglycaemia and hyperlipidaemia) and progressive renal injury [[8], [126]].

In the tubulointerstitium (Figure 1(a)), tubular hypertrophy and associated basement membrane alterations (thickening and irregularity) precede interstitial fibrosis, tubular atrophy (IFTA), and formation of hyaline cylinders, which accompany progressive renal dysfunction (Figure 1(a)). There seems to be a correlation between aggravation of tubulointerstitial and glomerular lesions, which is suggested by the aggravation of both glomeruli and interstitium [[126]]. Interstitial enlargement also correlates with glomerular filtration, albuminuria, and mesangial expansion. It has been suggested that the accumulation of protein in the cytoplasm of proximal tubular cells causes an inflammatory reaction which leads to tubulointerstitial lesions [[64], [163]].

Arteriolar hyalinosis and arteriosclerosis are the main vascular lesions found in human DN and also in some experimental animal models of diabetes (Figure 2(a)), and similarly, also aggravate with disease progression [[126], [162]]. Various studies have shown that DPP-4 inhibition is able to improve renal lesions in experimental animal models. In fact, in the obese diabetic ZDF rat, sitagliptin treatment ameliorated glomerular, tubulointerstitial (Figure 1(b)), and vascular lesions (Figure 2(b)) [[126]]. Other studies have also reported that suppression of DPP-4 activity and/or protein expression resulted in an amelioration of kidney fibrosis, which was correlated with inhibition of EndMT and reduction of inflammatory and fibrotic markers [[164][166]]. Similar histopathological improvements with incretin therapies have been disclosed by other studies [[166][168]].

4.3. Renal Cytoprotective Effects of Sitagliptin

Several authors have been postulating that gliptins could theoretically avoid or delay diabetic complications [[40], [167][168]], namely, due to reduction of oxidative stress and inflammation, as well as by antiapoptotic and pro-proliferative properties on various organs and tissues, including the kidney [[101][103], [138], [171], [172]].

Considering that sitagliptin is not able to completely normalize hyperglycaemia in studies using low doses [[8], [103], [126]], an alternative mechanism for the beneficial effect on kidney function/lesions can occur by a direct tissue DPP-4 inhibition, via GLP-1-dependent and/or GLP-1-independent pathways. The GLP-1-dependent activity is reinforced by the expression of GLP-1R in the kidney. In fact, there are several mechanisms by which direct renoprotection could occur. GLP-1 has been associated with the protection of mesangial cells, as well as with the reestablishment of Na+, acid-base and fluid homeostasis, which contributes to BP lowering and, collectively, to renoprotection [[173][175]]. The GLP-1-independent effects have been associated with other known substrates of DPP-4, such as high mobility group box 1 protein (HMGB1), meprin β, neuropeptide Y (NPY), and peptide YY (PYY) [[76], [164]].

It is known that DPP-4 exhibits its enzymatic activity in both membrane-anchored cell-surface peptidase and as a smaller soluble form in blood plasma [[77], [131], [176]]. In fact, there are some studies suggesting that microvascular endothelial cells are the main sources of endogenous DPP-4 [[177], [178]]. In addition, in vitro studies showed that both DPP-4 mRNA expression and enzyme activity were enhanced by exposure of human glomerular endothelial cells to high glucose concentrations [[179][181]]. In agreement, our research group has recently demonstrated that diabetic rats present an increased protein expression of DPP-4 in the kidney, when compared to nondiabetic animals [[8]].

Experimental studies in ZDF rats showed that chronic hyperglycaemia is associated with increased proinflammatory cytokines, namely, IL-1β and TNF-α in the kidney [[8]]. These outcomes are corroborated by other authors that described an increased expression of those proinflammatory cytokines in the diabetic kidney [[58], [77], [182]], leading to enhanced vascular permeability, oxidative stress, renal hypertrophy, and tubulointerstitial lesions. DPP-4 inhibition by low-dose sitagliptin has prevented the inflammatory profile and the proapoptotic state observed in the diabetic rat kidney, which might justify the improvement in renal function and tissular lesions (glomerular, tubulointerstitial, and vascular lesions). In fact, sitagliptin was able to prevent the increase in both mRNA and protein levels of the proinflammatory cytokines IL-1β and TNF-α in the diabetic kidneys of ZDF rats [[8]].

In Wistar rats treated with low- or high-dose sitagliptin during 16 weeks, urinary albumin excretion rate (UAER), serum creatinine, and kidney hypertrophy were significantly decreased. However, creatinine clearance rate and active GLP-1 levels were increased, with more pronounced changes in the high-dose sitagliptin-treated animals. Glomerular lesions were also improved following sitagliptin treatment. Protein and mRNA expression levels of podocalyxin and GLP-1R were significantly increased in both groups, while expression of signal-regulated kinases 1/2 (ERK1/2) and transforming growth factor-β1 (TGF-β1) was decreased [[183]]. Podocalyxin is a negatively charged transmembrane glycosaminoglycan that covers the secondary foot processes of the podocytes, which by electrical repellence keeps adjacent foot processes separated, maintaining the urinary filtration barrier open. Podocalyxin depletion is inversely correlated to albuminuria [[64], [184]]. These overall results also confirm a delay in DN progression promoted by sitagliptin, possibly via the inhibition of ERK1/2 signalling which seems to be activated by AGEs and is implicated in epithelial-myofibroblast transition [[185]]; by decreased TGF-β1 expression, a cytokine associated with inflammatory responses in T2DM, which has been recognized to be involved in the development of glomerulosclerosis and interstitial fibrosis; and by increasing the interaction between GLP-1 and the GLP-1R [[186]].

Recently, in a study involving 164 DN patients treated with metformin, sitagliptin (100 mg, once a day) was able to decrease UAER, which presented a close correlation with markers of renal fibrosis: TGF-β1 and platelet-derived growth factor-BB (PDGF-BB) [[187]]. Furthermore, PDGF-BB mRNA has been found to be overexpressed in diabetic patients and is considered a factor for mesangial cell proliferation and induction of TGF-β1, which shows a profibrotic action, being involved in the development of renal hypertrophy and accumulation of extracellular matrix in DN [[188]]. In addition, DPP-4 inhibition is known to downregulate TGF-β1 expression in mesangial cells [[189]]. Li et al. [[190]] suggest that the renoprotective mechanism of sitagliptin may be due to a reduction in protein kinase B (PKB)/Akt levels, which are involved in apoptosis pathways and restoration of adenosine monophosphate-activated protein kinase (AMPK) activity in diverse physiological processes, including ion transport, podocyte function and cell growth and cellular energy homeostasis, inhibition of TGF-β1, fibronectin, and p38/ERK MAPK signalling pathways involved in the regulation of ECM expression.

The activation of signalling pathways linked to cell death resulting from chronic hyperglycaemia and to a state of low-grade chronic inflammation contributes to an increase in apoptosis. A proapoptotic state seems to be favoured in the kidney of diabetic ZDF rats, which appears to be mediated by Bax and Bid. Sitagliptin prevented the Bax to Bcl-2 (mRNA and protein) ratio increase and reversed the increase in Bid and TUNEL-positive cells induced by chronic hyperglycaemia in the kidneys of this animal model [[8]]. In addition, sitagliptin was able to ameliorate serum TG content, thus reducing lipotoxicity-evoked apoptosis in the kidney [[8], [190][193]].

Additionally, it has been demonstrated that glucose-induced ROS production initiates podocyte apoptosis and its depletion in vitro and in vivo, leading to DN [[49], [56], [194]]. Therefore, the reduction of oxidative stress afforded by sitagliptin could eventually reduce ROS production and the consequent risk of cell death. A study on renal ischemia reperfusion damage in diabetic rats found sitagliptin to significantly decrease lipid peroxidation, xanthine oxidase activity, myeloperoxidase activity, and nitric oxide levels in renal tissue in comparison to those in untreated rats. Antioxidant enzymes like glutathione, glutathione peroxidase, superoxide dismutase, and catalase were significantly increased in sitagliptin-treated diabetic rats compared to those in the nontreated ones [[195]]. Other studies have demonstrated that GLP-1 receptor activation has also attenuated diabetic renal injury by reduction of kidney oxidative stress, inflammation, and apoptosis [[196][199]].

5. Concluding Remarks

The innovative class of DPP-4 inhibitors, such as sitagliptin, seem to address previously unmet needs in diabetes. In fact, DPP-4 has the highest expression levels in the kidneys of mammals, which is additionally upregulated in diabetic-induced CKD, indicating that DPP-4 inhibition by sitagliptin is a plausible therapeutic target for management of DN. In fact, several studies have been describing putative pleiotropic effects of sitagliptin on various organs and tissues. Sitagliptin showed not only the capacity to ameliorate diabetic dysmetabolism but also the potential to avert the decline of insulin secretion ability in pancreatic beta-cells through cytoprotective properties; these effects suggest a role in prevention of T2DM evolution and its complications. In the kidney, sitagliptin seems to provide renoprotection by restoring GLP-1 diuretic and natriuretic actions and by other mechanisms, including antiapoptotic, antifibrotic, anti-inflammatory, and antioxidant effects. However, additional studies are needed to clarify whether sitagliptin acts through indirect action via insulin secretion increment or through direct tissular DPP-4 inhibition. In addition, further research should also elucidate the contribution of GLP-1-dependent (which is sustained by expression of DPP-4 and GLP-1R in renal tissues) and/or GLP-1-independent pathways (reinforced by the existence of multiple DPP-4 substrates).

Due to its unique mechanism of action and pharmacological properties, DPP-4 inhibitors (including sitagliptin) have conquered their place in T2DM management. In addition, the low potential for interactions with other antidiabetic drugs allows its use in different combinations, with a low risk of hypoglycaemiac episodes. A fixed-dose combination with sodium/glucose cotransporter 2 (SLGT2) inhibitor ertugliflozin has been recently accepted and seems to contain the potential to exert further beneficial effects on the kidney, as both classes have been reported to lower UAER. Additional positive effects could be expected from the complementary mechanism of action of these drugs, with impact on both renal and cardiovascular systems. Disclosure of its protective actions on the diabetic kidney could open up the possibility of using sitagliptin therapy as a renoprotective strategy against the development and/or delay of DN.



The authors gratefully acknowledge the Portuguese Foundation for Science and Technology (FCT) through the projects PEst-C/SAU/UI3282/2013, CNC.IBILI Strategic Project (2015-UID/NEU/04539/2013), and the Operational Programme Competitiveness Factors (COMPETE-FEDER): FCOMP-01-0124-FEDER-028417 and POCI-01-0145-FEDER-007440, as well as Centro 2020 Regional Operational Programmes (CENTRO-01-0145-FEDER-000012: HealthyAging2020 and CENTRO-01-0145-FEDER-000008: BrainHealth 2020). Cristina Mega also thanks PROTEC grant by the Polytechnic Institute of Viseu (IPV) (PROTEC-SFRH/BD/50139/2009).


  1. M. VirallyJ. F. BlickléJ. GirardS. HalimiD. SimonP. J. GuillausseauType 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectivesDiabetic Medicine20073323124410.1016/j.diabet.2007.07.0012-s2.0-3454883547817703979
  2. S. E. KahnThe importance of the β-cell in the pathogenesis of type 2 diabetes mellitusAmerican Journal of Medicine20001082S8S10764844
  3. P. MarchettiR. LupiS. D. GuerraM. BuglianiL. MarselliU. BoggiThe β-cell in human type 2 diabetesAdvances in Experimental Medicine and Biology201065450151410.1007/978-90-481-3271-3_222-s2.0-7795395717220217512
  4. M. E. CerfBeta cell dysfunction and insulin resistanceFrontiers in Endocrinology20134p. 3710.3389/fendo.2013.000372-s2.0-84884193035
  5. S. YagihashiW. InabaH. MizukamiDynamic pathology of islet endocrine cells in type 2 diabetes: b-cell growth, death, regeneration and their clinical implicationsJournal of Diabetes Investigation2016715516510.1111/jdi.124242-s2.0-8495947390127042265
  6. R. A. D. FronzoFrom the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus (banting lecture)Diabetes20095877379510.2337/db09-90282-s2.0-6464910415819336687
  7. D. J. DruckerThe biology of incretin hormonesCell Metabolism20063315316510.1016/j.cmet.2006.01.0042-s2.0-3364461843316517403
  8. C. MarquesC. MegaA. GonçalvesSitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsMediators of Inflammation201420141553873710.1155/2014/5387372-s2.0-8489989545424817793
  9. M. K. PiyaP. G. McTernanS. KumarAdipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxinJournal of Endocrinology2013216T1T1510.1530/JOE-12-04982-s2.0-8487442824023160966
  10. S. GuoInsulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanismsJournal of Endocrinology2014220T1T2310.1530/JOE-13-03272-s2.0-8489305176624281010
  11. U. J. JungM.-S. ChoiObesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver diseaseInternational Journal of Molecular Sciences20141546184622310.3390/ijms150461842-s2.0-8489863884424733068
  12. S. L. LayG. SimardM. C. MartinezR. AndriantsitohainaOxidative stress and metabolic pathologies: from an adipocentric point of viewOxidative Medicine and Cellular Longevity201420141890853910.1155/2014/9085392-s2.0-8492588333225143800
  13. L. ChenR. ChenH. WangF. LiangMechanisms linking inflammation to insulin resistanceInternational Journal of Endocrinology20152015950840910.1155/2015/5084092-s2.0-8493434323926136779
  14. S. TangvarasittichaiOxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitusWorld Journal of Diabetes20156345648010.4239/wjd.v6.i3.45625897356
  15. K. N. KeaneV. F. CruzatR. CarlessiP. I. H. de BittencourtP. NewsholmeMolecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunctionOxidative Medicine and Cellular Longevity201520151518164310.1155/2015/1816432-s2.0-8493815322526257839
  16. E. J. BaeDPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose controlArchives of Pharmacal Research20163981114112810.1007/s12272-016-0813-x2-s2.0-8498126751327502601
  17. L. A. FillaJ. L. EdwardsMetabolomics in diabetic complicationsMolecular BioSystems2016121090110510.1039/c6mb00014b2-s2.0-8496205295926891794
  18. A. ChawlaR. ChawlaS. JaggiMicrovasular and macrovascular complications in diabetes mellitus: distinct or continuum?Indian Journal of Endocrinology and Metabolism201620454655110.4103/2230-8210.1834802-s2.0-8497504709827366724
  19. A. MimaIncretin-based therapy for prevention of diabetic vascular complicationsJournal of Diabetes Research2016201612137927410.1155/2016/13792742-s2.0-8495707065326881236
  20. T. S. KernContributions of inflammatory processes to the development of the early stages of diabetic retinopathyJournal of Diabetes Research20072007149510310.1155/2007/9510318274606
  21. J. F. Navarro-GonzálezC. Mora-FernándezThe role of inflammatory cytokines in diabetic nephropathyJournal of the American Society of Nephrology20081943344210.1681/ASN.20070910482-s2.0-4044911352418256353
  22. A. M. VincentB. C. CallaghanA. L. SmithE. L. FeldmanDiabetic neuropathy: cellular mechanisms as therapeutic targetsNature Reviews Neurology2011757358310.1038/nrneurol.2011.1372-s2.0-8055513114821912405
  23. M. NarresH. ClaessenS. DrosteThe incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic reviewPLoS One2016111, article e014732910.1371/journal.pone.01473292-s2.0-8495821178126812415
  24. J. A. J. G. Van den BrandDiabetes mellitus as a cause of end-stage renal disease in Europe: signs of improvementClinical Kidney Journal20169345445610.1093/ckj/sfw0292-s2.0-8497895818827274833
  25. American Diabetes AssociationStandards of medical care in diabetes—2017Diabetes Care201740Supplement 1
  26. M. Y. DonathD. M. SchumannM. FaulenbachH. EllingsgaardA. PerrenJ. A. EhsesIslet inflammation in type 2 diabetes: from metabolic stress to therapyDiabetes Care2008312S161S16410.2337/dc08-s24318227479
  27. W. J. RejeskiE. H. IpA. G. BertoniLifestyle change and mobility in obese adults with type 2 diabetesNew England Journal of Medicine2012366131209121722455415
  28. J. J. Marín-PeñalverI. Martín-TimónC. Sevillano-CollantesF. J. del Cañizo-GómezUpdate on the treatment of type 2 diabetes mellitusWorld Journal of Diabetes201671735439510.4239/wjd.v7.i17.35427660695
  29. R. KhardoriType 2 diabetes mellitus medicationMedscape, May 2017,
  30. R. GodinhoC. MegaE. Teixeira-de-LemosThe place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “me too” or “the special one” antidiabetic class?Journal of Diabetes Research201520152880697910.1155/2015/8069792-s2.0-8493096555526075286
  31. International Diabetes Federation (IDF) 2014
  32. D. M. NathanP. McGeeM. W. SteffesJ. M. LachinDCCT/EDIC Research GroupRelationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC studyDiabetes20146328229023990364
  33. National Institute for Health and Care Excellence (NICE)Type 2 diabetes in adults: management. NICE guidelines [NG28] 2015April 2017,
  34. American Diabetes Association (ADA)Strategies for Improving CareDiabetes Care201639Supplement 1S6S1226696683
  35. S. AyaduraiH. L. HattinghL. B. G. TeeS. N. Md SaidA narrative review of diabetes intervention studies to explore diabetes care opportunities for pharmacistsJournal of Diabetes Research2016201611589745210.1155/2016/58974522-s2.0-8497334302327247949
  36. G. RaymanGlycaemic control, glucose variability and the triangle of diabetes careBritish Journal of Diabetes201616Supplement 1S3S610.15277/bjd.2016.0702-s2.0-84971443009
  37. S. E. KahnM. E. CooperS. D. PratoPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureThe Lancet20143831068108310.1016/S0140-6736(13)62154-62-s2.0-8489649571924315620
  38. S. E. InzucchiR. M. BergenstalJ. B. BuseManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137910.2337/dc12-04132-s2.0-8486560644022517736
  39. M. Mata-CasesD. MauricioJ. Franch-NadalClinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targetsJournal of Diabetes201791344410.1111/1753-0407.1237326749415
  40. D. Russell-JonesS. GoughRecent advances in incretin-based therapiesClinical Endocrinology201277448949910.1111/j.1365-2265.2012.04483.x2-s2.0-8486730493422804841
  41. B. L. Wajchenbergβ-cell failure in diabetes and preservation by clinical treatmentEndocrine Reviews201728218721817353295
  42. W. T. CefaluThe physiologic role of incretin hormones: clinical applicationsJournal of the American Osteopathic Association20101103Supplement 2S8S1420382839
  43. M. C. RiddleGlycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinationsEndocrinology and Metabolism Clinics of North America200534779810.1016/j.ecl.2004.12.0022-s2.0-1474428739415752923
  44. A. A. HasanB. HocherRole of soluble and membrane-bound dipeptidylpeptidase-4 in diabetic nephropathyJournal of Molecular Endocrinology2017591R1R1010.1530/JME-17-000528420715
  45. J. E. GerichRole of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implicationsDiabetic Medicine201027213614210.1111/j.1464-5491.2009.02894.x2-s2.0-7624913390320546255
  46. M. A. NauckUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Design Development and Therapy2014813351380
  47. H. NohG. L. KingThe role of protein kinase C activation in diabetic nephropathyKidney International2007106S49S5310.1038/
  48. N. TanjiG. S. MarkowitzC. FuExpression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal diseaseJournal of the American Society of Nephrology20001191656166610966490
  49. K. SusztakA. C. RaffM. SchifferE. P. BöttingerGlucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathyDiabetes200655122523316380497
  50. J. M. ForbesM. T. CoughlanM. E. CooperOxidative stress as a major culprit in kidney disease in diabetesDiabetes20085761446145410.2337/db08-00572-s2.0-4824908539118511445
  51. Z. CaoM. E. CooperPathogenesis of diabetic nephropathyJournal of Diabetes Investigation20112424324710.1055/s-2001-186002-s2.0-003497776524843491
  52. D. K. SinghP. WinocourK. FarringtonOxidative stress in early diabetic nephropathy: fueling the fireNature Reviews Endocrinology20117317618410.1038/nrendo.2010.2122-s2.0-7995218637021151200
  53. X. ChenZ. RenW. Liangc-Abl mediates angiotensin II-induced apoptosis in podocytesJournal of Molecular Histology201344559760810.1007/s10735-013-9505-82-s2.0-8487502135123515840
  54. V. P. SinghA. BaliN. SinghA. S. JaggiAdvanced glycation end products and diabetic complicationsThe Korean Journal of Physiology & Pharmacology201418111410.4196/kjpp.2014.18.1.12-s2.0-8489652886024634591
  55. A. RiveroC. MoraM. MurosJ. GarcíaH. HerreraJ. F. Navarro-GonzálezPathogenic perspectives for the role of inflammation in diabetic nephropathyClinical Science2009116647949210.1042/CS200803942-s2.0-6524910217919200057
  56. P. GaoF.-F. HeH. TangNADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemiaJournal of Diabetes Research201520151250476110.1155/2015/5047612-s2.0-8492532175525834832
  57. K. KanasakiG. TaduriD. KoyaDiabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosisFrontiers in Endocrinology20134p. 710.3389/fendo.2013.000072-s2.0-8488076576823390421
  58. M. B. Duran-SalgadoA. F. Rubio-GuerraDiabetic nephropathy and inflammationWorld Journal of Diabetes20145339339810.4239/wjd.v5.i3.39324936261
  59. S. MoranoR. CiprianiC. SantangeloAngiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathyClinical Therapeutics2008159315115418594743
  60. T. ChawlaD. SharmaA. SinghRole of the renin angiotensin system in diabetic nephropathyWorld Journal of Diabetes20101514114510.4239/wjd.v1.i5.14121537441
  61. M. H. A. MuskietM. M. SmitsL. M. MorsinkM. DiamantThe gut–renal axis: do incretin-based agents confer renoprotection in diabetes?Nature Reviews Nephrology2014108810310.1038/nrneph.2013.2722-s2.0-8489507227924375052
  62. S. M. MarshallRecent advances in diabetic nephropathyPostgraduate Medical Journal20048062463310.1136/pgmj.2004.0212872-s2.0-914423300915537844
  63. E. BortolosoD. D. PreteM. Dalla VestraQuantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetesEuropean Journal of Endocrinology200415079980715191350
  64. H. J. BaeldeM. EikmansD. W. LappinReduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte lossKidney International20077163764510.1038/
  65. J. J. LiS. J. KwakD. S. JungPodocyte biology in diabetic nephropathyKidney International2007106S36S4210.1038/
  66. J. S. LinK. SusztakPodocytes: the weakest link in diabetic kidney disease?Current Diabetes Reports2016165p. 4510.1007/s11892-016-0735-52-s2.0-8496277464127053072
  67. J. R. SowersA. Whaley-ConnellM. R. HaydenThe role of overweight and obesity in the cardiorenal syndromeCardiorenal Medicine2011151222258461
  68. P. SchlatterC. BeglingerJ. DreweH. GutmannGlucagon-like peptide 1 receptor expression in primary porcine proximal tubular cellsRegulatory Peptides200714112012810.1016/j.regpep.2006.12.0162-s2.0-3394758461917276524
  69. A. AroorS. McKarnsR. NistalaDPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetesCardiorenal Medicine201331485610.1159/0003487562-s2.0-8489654545823946724
  70. M. YuC. MorenoK. M. HoaglandAntihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive ratsJournal of Hypertension2003211125113510.1097/01.hjh.0000059046.65882.4912777949
  71. E. P. JensenS. S. PoulsenH. KissowActivation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flowAmerican Journal of Physiology - Renal Physiology20153088F867F87710.1152/ajprenal.00527.20142-s2.0-8492774017025656368
  72. T. A. SallesL. dos SantosV. G. BaraunaA. C. C. GirardiPotential role of dipeptidyl peptidase IV in the pathophysiology of heart failureInternational Journal of Molecular Sciences20151624226424910.3390/ijms160242262-s2.0-8492309883925690036
  73. E. E. MulvihillD. J. DruckerMetabolic implications of DPP-4 inhibitionEndocrine Reviews2014356992101925216328
  74. K. V. WebskyC. ReichetzederaB. HocheraPhysiology and pathophysiology of incretins in the kidneyCurrent Opinion in Nephrology and Hypertension2014231546010.1097/01.mnh.0000437542.77175.a02-s2.0-8489051859124257158
  75. S. ShiD. KoyaK. KanasakiDipeptidyl peptidase-4 and kidney fibrosis in diabetesFibrogenesis & Tissue Repair20169p. 110.1186/s13069-016-0038-02-s2.0-8495762980326877767
  76. G. P. FadiniE. BoscaroM. AlbieroThe oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1αDiabetes Care2010331607160910.2337/dc10-01872-s2.0-7795819599720357375
  77. G. L. PloskerSitagliptin: a review of its use in patients with type 2 diabetes mellitusDrugs20147422324210.1007/s40265-013-0169-12-s2.0-8489573641024407560
  78. G. A. HermanC. StevensK. Van DyckPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesJournal of Clinical Pharmacology and Therapeutics200578667568810.1016/j.clpt.2005.09.0022-s2.0-2884448232216338283
  79. A. J. BergmanJ. CoteB. YiEffect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitorDiabetes Care20073071862186417468348
  80. E. M. MigoyaC. H. StevensA. J. BergmanEffect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptinCanadian Journal of Clinical Pharmacology200916116517019221403
  81. J. C. Arjona FerreiraM. MarreN. BarzilaiEfficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyDiabetes Care20133651067107310.2337/dc12-13652-s2.0-8487678512523248197
  82. J. J. NeumillerI. B. HirschManagement of hyperglycemia in diabetic kidney diseaseDiabetes Spectrum201528321421910.2337/diaspect.28.3.2142-s2.0-8496405755526300616
  83. C. C. R. BetônicoS. M. O. TitanM. L. C. Correa-GiannellaM. NeryM. QueirozManagement of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic controlClinics2016711475310.6061/clinics/2016(01)082-s2.0-8495760650426872083
  84. D. KimL. WangM. Beconi2(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1, 2, 4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesJournal of Medicinal Chemistry200548114115115634008
  85. S. E. InzucchiD. K. McGuireNew drugs for the treatment of diabetes: part II. Incretin-based therapy and beyondCirculation2008117457458410.1161/CIRCULATIONAHA.107.7357952-s2.0-4104911080318227398
  86. B. AhrénDipeptidyl peptidase-4 inhibitors: clinical data and clinical implicationsDiabetes Care20073061344135010.2337/dc07-02332-s2.0-3424986844617337494
  87. R. K. CampbellRationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitusAnnals of Pharmacotherapy2007411516017190843
  88. J. RosenstockB. ZinmanDipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitusCurrent Opinion in Endocrinology, Diabetes, and Obesity20071429810710.1097/MED.0b013e3280a02f652-s2.0-3384768571417940427
  89. L. L. BaggioD. J. DruckerBiology of incretins: GLP-1 and GIPGastroenterology200713262131215710.1053/j.gastro.2007.03.0542-s2.0-3424822328517498508
  90. J. F. GautierS. P. ChoukemJ. GirardPhysiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetesDiabetes & Metabolism200834Supplement 2S65S7210.1016/S1262-3636(08)73397-42-s2.0-4764909500418640588
  91. C. F. DeaconP. DanielsenL. KlarskovM. OlesenJ. J. HolstDipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigsDiabetes20015071588159711423480
  92. G. A. HermanA. BergmanF. LiuPharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjectsJournal of Clinical Pharmacology200646887688610.1177/00912700062898502-s2.0-3374590943216855072
  93. B. AhrénE. SimonssonH. LarssonInhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetesDiabetes Care200225586987511978683
  94. B. AhrénInsulin plus incretin: a glucose-lowering strategy for type 2-diabetesWorld Journal of Diabetes201451405110.4239/wjd.v5.i1.4024567800
  95. A. J. ScheenPharmacokinetics of dipeptidylpeptidase-4 inhibitorsDiabetes Obesity and Metabolism201012864865810.1111/j.1463-1326.2010.01212.x2-s2.0-7795545670520590741
  96. S. S. EngelE. RoundG. T. GolmK. D. KaufmanB. J. GoldsteinSafety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studiesDiabetes Therapy20134111914510.1007/s13300-013-0024-02-s2.0-8488538464523700194
  97. K. GargC. D. TripathiS. KumarClinical review of sitagliptin: a DPP-4 inhibitorJournal of the Association of Physicians of India201361576124772702
  98. K. EspositoP. ChiodiniM. I. MaiorinoG. BellastellaA. CapuanoD. GiuglianoGlycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trialsBMJ Open20144, article e00544210.1136/bmjopen-2014-0054422-s2.0-8490321180024916090
  99. J. MuJ. WoodsY. P. ZhouChronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetesDiabetes20065561695170410.2337/db05-16022-s2.0-3374833119416731832
  100. J. MuA. PetrovG. J. EiermannInhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetesEuropean Journal of Pharmacology200962314815410.1016/j.ejphar.2009.09.0272-s2.0-7035020395219765579
  101. L. FerreiraE. Teixeira-de-LemosF. PintoEffects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)Mediators of Inflammation201020101159276010.1155/2010/5927602-s2.0-7795540646720652060
  102. M. JiL. XiaJ. CaoD. ZouSitagliptin/metformin versus insulin glargine combined with metformin in obese subjects with newly diagnosed type 2 diabetesMedicine20169511, article e296110.1097/MD.00000000000029612-s2.0-8496199040126986104
  103. Y. KondoN. HaradaA. HamasakiSitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trialDiabetology & Metabolic Syndrome201681510.1186/s13098-016-0131-y2-s2.0-8495936134026925169
  104. X. RenG. LiuY. WangInfluence of dipeptidyl peptidase-IV inhibitor sitagliptin on extracellular signal-regulated kinases 1/2 signaling in rats with diabetic nephropathyPharmacology201710011310.1159/00045587428329747
  105. B. GallwitzExtra-pancreatic effects of incretin-based therapiesEndocrine201447236037110.1007/s12020-014-0223-02-s2.0-8491100508724604239
  106. E. J. VerspohlNovel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like-peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitorsPharmacology & Therapeutics200912411313810.1016/j.pharmthera.2009.06.0022-s2.0-6894915982919545590
  107. R. E. Van GenugtenD. H. van RaalteM. DiamantDipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidenceDiabetes Obesity and Metabolism20121410111110.1111/j.1463-1326.2011.01473.x2-s2.0-8345523003921752172
  108. Y. ZengC. LiM. GuanThe DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanismsCardiovascular Diabetology2014133210.1186/1475-2840-13-322-s2.0-8489316295824490809
  109. A. V. MatveyenkoS. DryH. I. CoxBeneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metforminDiabetes20095871604161510.2337/db09-00582-s2.0-6765024553119403868
  110. Y. S. LiuZ. W. HuangL. WangSitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic ratsJournal of Pharmacological Sciences2015127326027410.1016/j.jphs.2014.12.0072-s2.0-8493687623625837922
  111. L. M. McCormickA. C. KyddP. A. ReadChronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery diseaseCirculation: Cardiovascular Imaging20147227428110.1161/CIRCIMAGING.113.0007852-s2.0-8490041033924503784
  112. N. ApaijaiH. PintanaS. C. ChattipakornN. ChattipakornEffects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin resistant ratsBritish Journal of Pharmacology201316951048105723488656
  113. B. PicatosteE. RamírezA. Caro-VadilloSitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoformsPLoS One2013810, article e7833010.1371/journal.pone.00783302-s2.0-8488690073724302978
  114. P. A. ReadF. Z. KhanP. M. HeckS. P. HooleD. P. DutkaDPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery diseaseCirculation. Cardiovascular Imaging20103219520110.1161/CIRCIMAGING.109.8993772-s2.0-7795193494820075143
  115. M. T. KelleniE. F. AminA. M. AbdelrahmanEffect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosisJournal of Toxicology20152015842481310.1155/2015/4248132-s2.0-8495707579126880912
  116. T. MitaN. KatakamiT. ShiraiwaSitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (spike): a randomized controlled trialDiabetes Care201639345546410.2337/dc15-21452-s2.0-8496209023226822324
  117. R. E. AmoriJ. LauA. G. PittasEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJournal of the American Medical Association2007298219420610.1001/jama.298.2.1942-s2.0-3444726751317622601
  118. M. FanY. LiS. ZhangEffects of sitagliptin on lipid profiles in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trialsMedicine20169521910.1097/MD.00000000000023862-s2.0-8495815235626765417
  119. P. C. M. Van PoppelM. G. NeteaP. SmitsC. TackVildagliptin improves endothelium-dependent vasodilatation in type 2 diabetesDiabetes Care20113492072207710.2337/dc10-24212-s2.0-8345523003821788633
  120. J. S. YoonH. W. LeeUnderstanding the cardiovascular effects of incretinDiabetes & Metabolism Journal201135543744310.4093/dmj.2011.35.5.4372-s2.0-8485947999322111033
  121. C. MegaH. ValaP. Rodrigues-SantosSitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker diabetic fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective propertiesDiabetology & Metabolic Syndrome201461p. 4210.1186/1758-5996-6-422-s2.0-8490168753124650557
  122. A. GonçalvesE. LealA. PaivaProtective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal modelDiabetes, Obesity and Metabolism201214545446310.1111/j.1463-1326.2011.01548.x2-s2.0-8485944400022151893
  123. A. GonçalvesC. MarquesE. LealDipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic ratsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease2014184291454146310.1016/j.bbadis.2014.04.0132-s2.0-8490348786424769045
  124. C. MegaE. T. de LemosH. ValaDiabetic nephropathy amelioration by a low dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat)Experimental Diabetes Research201120111216209210.1155/2011/1620922-s2.0-8485561150522203828
  125. A. MaidaT. HansotiaC. LonguetT. SeinoD. J. DruckerDifferential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for β cell survival in miceGastroenterology20091372146215710.1053/j.gastro.2009.09.0042-s2.0-7064909434619766644
  126. J. A. YeomE. S. KimH. S. ParkBoth sitagliptin analogue & pioglitazone preserve the β-cell proportion in the islets with different mechanism in non-obese and obese diabetic miceBMB Reports2011441171371822118536
  127. Y. TakedaY. FujitaJ. HonjoReduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in miceDiabetologia201255240441210.1007/s00125-011-2365-42-s2.0-8485671164322072158
  128. S. KarabulutZ. M. CoskunbS. BolkentImmunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic ratsPharmacological Reports201567584685310.1016/j.pharep.2015.01.0102-s2.0-8493979990226398375
  129. J. ShirakawaT. OkuyamaM. KyoharaDPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acidDiabetology & Metabolic Syndrome201681610.1186/s13098-016-0138-42-s2.0-8497876021426937254
  130. A. D. DobrianQ. MaJ. W. LindsayDipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese miceAmerican Journal of Physiology: Endocrinology and Metabolism20113002E410E42110.1152/ajpendo.00463.20102-s2.0-7925154115921081706
  131. N. Satoh-AsaharaY. SasakiH. WadaA dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patientsMetabolism201362334735110.1016/j.metabol.2012.09.0042-s2.0-8487411199223062489
  132. G. DerosaA. CarboneA. D’AngeloVariations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metforminInternal Medicine201352192179218724088749
  133. F. BeguinotTribbles homologue 3 (TRIB3) and the insulin-resistance genes in type 2 diabetesDiabetologia2010531831183410.1007/s00125-010-1824-72-s2.0-7795555291720567803
  134. S. PrudenteD. ScarpelliM. ChandaliaThe trib3 Q84R polymorphism and risk of early-onset type 2 diabetesJournal of Clinical Endocrinology & Metabolism200994119019610.1210/jc.2008-13652-s2.0-5814938946518984671
  135. J. ShirakawaH. FujiiK. OhnumaDiet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic miceDiabetes2011601246125710.2337/db10-13382-s2.0-7995321330421330637
  136. S. OyadomariH. P. HardingY. ZhangM. OyadomariD. RonDephosphorylation of translation initiation factor 2α enhances glucose tolerance and attenuates hepatosteatosis in miceCell Metabolism2008752053210.1016/j.cmet.2008.04.0112-s2.0-4434916399918522833
  137. V. AvivI. Meivar-LevyI. H. RachmutT. RubinekE. MorS. FerberExendin-4 promotes liver cell proliferation and enhances PDX-1-induced liver to pancreas transdifferentiationThe Journal of Biological Chemistry200928448335093352010.1074/jbc.M109.0176082-s2.0-7045023504119755420
  138. L. GaetanielloM. FioreS. de FilippoN. PozziS. TamasiC. PignataOccupancy of dipeptidyl peptidase IV activates an associated tyrosine kinase and triggers an apoptotic signal in human hepatocarcinoma cellsHepatology1998279349429537431
  139. M. E. KelanyT. M. HakamiA. H. OmarM. A. AbdallahCombination of sitagliptin and insulin against type 2 diabetes mellitus with neuropathy in rats: neuroprotection and role of oxidative and inflammation stressPharmacology20169824225010.1159/0004480432-s2.0-8498032922527449930
  140. B. F. SchrijversA. FlyvbjergR. G. TiltonN. H. LameireA. S. D. VrieseA neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty ratNephrology Dialysis Transplantation200621232432910.1093/ndt/gfi2172-s2.0-3154443394116249198
  141. L. LiuJ. LiuW. T. WongDipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanismHypertension20126083384110.1161/HYPERTENSIONAHA.112.1951152-s2.0-8486549297022868389
  142. S. Kröller-SchönM. KnorrM. HausdingGlucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibitionCardiovascular Research20129614014910.1093/cvr/cvs2462-s2.0-8486664496522843705
  143. I. KawasakiY. HiuraA. TamaiSitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rateJournal of Diabetes201571414610.1111/1753-0407.121532-s2.0-8492011225324661437
  144. L. M. RussoR. M. SandovalS. B. CamposB. A. MolitorisW. D. ComperD. BrownImpaired tubular uptake explains albuminuria in early diabetic nephropathyJournal of the American Society of Nephrology200920348949410.1681/ASN.20080505032-s2.0-6214912294019118149
  145. G. B. PeresY. M. MichelacciThe role of proximal tubular cells in the early stages of diabetic nephropathyJournal of Diabetes & Metabolism20156p. 551
  146. A. C. GirardiB. C. DegrayT. NagyD. BiemesderferP. S. AronsonAssociation of Na+-H+ exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubuleThe Journal of Biological Chemistry200127649466714667710.1074/jbc.M1068972002-s2.0-003582461411590171
  147. D. F. Arruda-JuniorF. L. MartinsR. DariolliDipeptidyl peptidase IV inhibition exerts renoprotective effects in rats with established heart failureFrontiers in Physiology20167p. 29310.3389/fphys.2016.002932-s2.0-8498150838527462276
  148. R. NistalaJ. HabibiG. LastraPrevention of obesity-induced renal injury in male mice by DPP4 inhibitionEndocrinology201415562266227610.1210/en.2013-19202-s2.0-8490145305924712875
  149. R. NistalaJ. HabibiA. AroorDPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese ratObesity201422102172217910.1002/oby.208332-s2.0-8490788335824995775
  150. W. J. LiuS. H. XieY. N. LiuDipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic ratsJournal of Pharmacology and Experimental Therapeutics201234024825510.1124/jpet.111.1868662-s2.0-8486294405722025647
  151. A. AroorM. ZuberekC. DutaAngiotensin II stimulation of DPP4 activity regulates megalin in the proximal tubulesInternational Journal of Molecular Sciences201617510.3390/ijms170507802-s2.0-8498213099627213360
  152. B. HocherC. ReichetzederM. L. AlterRenal and cardiac effects of DPP-4 inhibitors – from preclinical development to clinical researchKidney and Blood Pressure Research201236658410.1159/0003390282-s2.0-8486557686322947920
  153. B. P. PachecoR. O. CrajoinasG. K. CoutoDipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive ratsJournal of Hypertension20112952052810.1097/HJH.0b013e328341939d2-s2.0-7995167709521150640
  154. S. SahaY. LiM. B. Anand-SrivastavaReduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive ratsCanadian Journal of Physiology and Pharmacology20088619019810.1139/Y08-0122-s2.0-4214913420918418428
  155. A. AvogaroG. P. FadiniThe effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complicationsDiabetes Care201437102884289410.2337/dc14-08652-s2.0-8490819924225249673
  156. A. A. EddySerine proteases, inhibitors and receptors in renal fibrosisThrombosis and Haemostasis2009101465666419350108
  157. G. TramontiY. S. KanwarTubular biomarkers to assess progression of diabetic nephropathyKidney International201179101042104410.1038/ki.2011.92-s2.0-7995559511221527942
  158. S. HoshiY. ShuF. YoshidaPodocyte injury promotes progressive nephropathy in zucker diabetic fatty ratsLaboratory Investigation2002821253511796823
  159. N. GasslerM. ElgerB. KränzlinPodocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker ratKidney International200160110611610.1046/j.1523-1755.2001.00777.x2-s2.0-003494993311422742
  160. T. W. TervaertA. L. MooyaartK. AmannPathologic classification of diabetic nephropathyJournal of the American Society of Nephrology201021455656310.1681/ASN.20100100102-s2.0-7795060155620167701
  161. K. WhiteHistological appearance of diabetic nephropathyDiapedia 7105002828 rev.2014510.14496/dia.7105002828.5
  162. U. PanchapakesanC. PollockThe role of dipeptidyl peptidase – 4 inhibitors in diabetic kidney diseaseFrontiers in Immunology20156p. 44310.3389/fimmu.2015.004432-s2.0-8494127219026379674
  163. H. S. MinJ. E. KimM. H. LeeDipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstructionLaboratory Investigation201494659860710.1038/labinvest.2014.502-s2.0-8490417262324687121
  164. S. ShiS. P. SrivastavaM. KanasakiInteractions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transitionKidney International201588347948910.1038/ki.2015.1032-s2.0-8494079123525830763
  165. G. TonoloS. CherchiTubulointerstitial disease in diabetic nephropathyInternational Journal of Nephrology and Renovascular Disease2014710711510.2147/IJNRD.S378832-s2.0-8489700846124711709
  166. P. VavrinecR. H. HenningS. W. LandheerVildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty ratCurrent Vascular Pharmacology20141283684424066937
  167. I. RazM. HanefeldL. XuEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia200649112564257117001471
  168. V. GuptaS. KalraChoosing a gliptinIndian Journal of Endocrinology and Metabolism201115429830810.4103/2230-8210.8558322029001
  169. Y. WangS. LandheerW. H. van GilstAttenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP-4-inhibitory activityPLoS One2012710, article e4678110.1371/journal.pone.00467812-s2.0-84867351013
  170. H. Y. JinW. J. LiuJ. H. ParkH. S. BaekT. S. ParkEffect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic ratsArchives of Medical Research20094053654410.1016/j.arcmed.2009.09.0052-s2.0-7164910275120082866
  171. Y. IshibashiS. YamagishiT. MatsuiPravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) levelMetabolism2012611067107210.1016/j.metabol.2012.01.0062-s2.0-8486428767222386936
  172. T. TanakaY. HigashijimaT. WadaM. NangakuThe potential for renoprotection with incretin-based drugsKidney International20148670171110.1038/ki.2014.2362-s2.0-8492619723625007170
  173. J. L. GórrizJ. NietoJ. F. Navarro-GonzálezP. MolinaA. Martínez-CastelaoL. M. PallardóNephroprotection by hypoglycemic agents: do we have supporting data?Journal of Clinical Medicine20154101866188910.3390/jcm410186626512703
  174. W. S. Silva JúniorA. F. Godoy-MatosL. G. Kraemer-AguiarDipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis?Biomedical Research International201520151081616410.1155/2015/8161642-s2.0-8493495710726146634
  175. V. MatheeussenL. BaertsG. De MeyerExpression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillariesBiological Chemistry2011392318919810.1515/BC.2011.0022-s2.0-7995332008521194356
  176. T. RomachoS. VallejoL. A. VillalobosSoluble dipeptidyl peptidase-4 induces microvascular endothelial dysfunction through proteinase-activated receptor-2 and thromboxane A2 releaseJournal of Hypertension201634586987610.1097/HJH.00000000000008862-s2.0-8495879393926895560
  177. C. G. YuN. ZhangS. S. YuanEndothelial progenitor cells in diabetic microvascular complications: friends or foes?Stem Cells International2016201610180398910.1155/2016/18039892-s2.0-8497526670227313624
  178. R. H. AhmedH. Z. HuriZ. Al-HamodiS. D. SalemS. MuniandySerum levels of soluble CD26/dipeptidyl peptidase-IV in type 2 diabetes mellitus and its association with metabolic syndrome and therapy with antidiabetic agents in Malaysian subjectsPLoS One20151010, article e014061810.1371/journal.pone.01406182-s2.0-8494948235026474470
  179. D. RöhrbornN. WronkowitzJ. EckelDPP-4 in diabetesFrontiers in Immunology20156p. 38610.3389/fimmu.2015.003862-s2.0-84938537260
  180. J. Donate-CorreaE. Martín-NúñezM. Muros-de-FuentesC. Mora-FernándezJ. F. Navarro-GonzálezInflammatory cytokines in diabetic nephropathyJournal of Diabetes Research20152015994841710.1155/2015/9484172-s2.0-84924246974
  181. J. F. NavarroC. MoraDiabetes, inflammation, proinflammatory cytokines, and diabetic nephropathyThe Scientific World Journal2006690891710.1100/tsw.2006.1792-s2.0-3374738529116906324
  182. X. RenG. LiuY. WangInfluence of dipeptidyl peptidase-iv inhibitor sitagliptin on extracellular signal-regulated kinases 1/2 signaling in rats with diabetic nephropathyPharmacology20171001-211310.1159/00045587428329747
  183. J. S. NielsenK. M. McNagnyNovel functions of the CD34 familyJournal of Cell Science2008121Part 223682369210.1242/jcs.0375072-s2.0-5954910045218987355
  184. J. H. LiW. WangX. R. HuangAdvanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathwayThe American Journal of Pathology200416441389139710.1016/S0002-9440(10)63225-715039226
  185. K. B. GomesK. F. RodriguesA. P. FernandesThe role of transforming growth factor-beta in diabetic nephropathyInternational Journal of Medical Genetics20142014618027010.1155/2014/180270
  186. F. YangT. YuK. LiX. JiangJ. LiJ. WangSitagliptin reduces transforming growth factor-β1 and platelet derived growth factor-BB in regulation of UAER in type 2 diabetic nephropathy stage III patientsBiomedical Research201728625712577
  187. S. S. BessaT. A. HusseinM. A. MoradA. M. AmerUrinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian studyRenal Failure201234667067510.3109/0886022X.2012.6744382-s2.0-8486222712722486214
  188. Y. IshibashiY. NishinoT. MatsuiM. TakeuchiS. I. YamagishiGlucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor levelMetabolism20116091271127710.1016/j.metabol.2011.01.0102-s2.0-8005180078121388644
  189. J. LiM. GuanC. LiThe dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout miceInternational Journal of Molecular Sciences201415114161143410.3390/ijms1507114162-s2.0-8490338609724972137
  190. H. S. LeeMechanisms and consequences of hypertriglyceridemia and cellular lipid accumulation in chronic kidney disease and metabolic syndromeHistology and Histopathology201126121599161010.14670/HH-26.159921972098
  191. A. R. MartinsS. MasLipotoxicity and kidneyPortuguese Journal of Nephrology & Hypertension2015294306315
  192. S. J. GlastrasH. ChenR. T. McGrathEffect of GLP-1 receptor activation on offspring kidney health in a rat model of maternal obesityScientific Reports20166, article 2352510.1038/srep235252-s2.0-8496232064227004609
  193. F. A. WagenerD. DekkerJ. H. BerdenA. ScharstuhlJ. van der VlagThe role of reactive oxygen species in apoptosis of the diabetic kidneyApoptosis200914121451145810.1007/s10495-009-0359-12-s2.0-7044912203319466552
  194. M. D. Sanchez-NiñoA. Benito-MartinA. OrtizNew paradigms in cell death in human diabetic nephropathyKidney International201078873774410.1038/ki.2010.2702-s2.0-7795759536920703212
  195. J. VaghasiyaN. ShethY. BhalodiaR. ManekSitagliptin protects renal ischemia reperfusion induced renal damage in diabetesRegulatory Peptides20111661–3485410.1016/j.regpep.2010.08.0072-s2.0-7865017580220728477
  196. H. HendartoT. InoguchiY. MaedaGLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A mediated inhibition of renal NAD(P)H oxidasesMetabolism201261101422143410.1016/j.metabol.2012.03.0022-s2.0-8486673269522554832
  197. R. KoderaK. ShikataT. TakasutaDipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its antiinflammatory action in a rat model of type 1 diabetesBiochemical and Biophysical Research Communications2014443382883310.1016/j.bbrc.2013.12.0492-s2.0-8489370428224342619
  198. S. NakashimaT. MatsuiM. TakeuchiS. I. YamagishiLinagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axisHormone and Metabolic Research20144671772110.1055/s-0034-13718922-s2.0-8492946987324710699
  199. T. MatsuiS. NakashimaY. NishinoDipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axisLaboratory Investigation201595552553310.1038/labinvest.2015.352-s2.0-8492907472325730373
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as maturity-onset diabetes of the young.